A Non-randomized, Multiple Dose, Three Treatment Period, Open-label, Single Sequence, Single Group Study to Evaluate the Pharmacokinetic Effect of Two Doses of QTI571 (Imatinib) on the Co-administered Drugs Sildenafil and Bosentan in Pulmonary Arterial Hypertension (PAH) Patients
Phase of Trial: Phase III
Latest Information Update: 19 Jun 2018
Price : $35 *
At a glance
- Drugs Imatinib (Primary) ; Bosentan; Sildenafil
- Indications Pulmonary arterial hypertension
- Focus Pharmacokinetics
- Sponsors Novartis Pharmaceuticals
- 12 Jun 2018 Status changed from discontinued to completed.
- 20 Feb 2017 Status changed from completed to discontinued.
- 21 Nov 2013 New trial record